Skip to main content
Canna~Fangled Abstracts

Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy

By June 7, 2024June 25th, 2024No Comments

Abstract

Introduction: Cannabinoids are approved for spasticity and pain in multiple sclerosis (MS). In 2017 the prevalence of current users in the Italian general population was 10.2%, while data on Italian MS patients are limited.

Methods: From March 2022 to February 2023, we conducted a multicenter, cross-sectional study. Adult MS patients completed an anonymous online survey. The primary outcome was the estimated prevalence of unprescribed cannabis current use. Cannabis use patterns and associations with clinical and socio-demographical variables were investigated. The binomial method was used to estimate 95% confidence interval (95% CI) for primary outcome.

Results: 5620 patients were invited and 2024 (36.0%) were included (mean age 45.2 years, females 64.5%). Relapsing remitting form was the most frequent (77.3%). Median expanded disability status scale (EDSS) was 2.0. The proportion of current users was 15.5% (95% CI 13.9-17.1) and 36.4% of them disclosed to their physician their unprescribed cannabis use. 15.0% patients were former users while 69.5% never used cannabis. Current users more frequently reported a medical use (i.e., current medical users) compared to former users (p < 0.001). 41.1% of never users would use cannabis if it was legal. Young age, being male, and a free marital status were associated with current use. Current medical users had higher disability, spasticity and pain, reduced quality of life, concomitant neurological/psychiatric drugs and analgesics use. Unprescribed cannabis appeared relatively safe, with limited addiction risk, and reported clinical benefits, including concomitant medications reduction.

Conclusion: Unprescribed cannabis use is common in patients with MS in Italy, with observed prevalence seemingly superior to the general population, often intended for medical use and without the disclosure to the treating physician, although with potential clinical benefits.

Keywords: Cannabis; Cross-sectional; Epidemiology; Multiple sclerosis.

PubMed Disclaimer

References

    1. Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378:169–180. https://doi.org/10.1056/NEJMra1401483 – DOI – PubMed – PMC
    1. Ueberall MA, Essner U, Mueller-Schwefe GH (2019) Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. J Pain Res 12:1577–1604. https://doi.org/10.2147/JPR.S192174 – DOI – PubMed – PMC
    1. Kleiner D, Horváth IL, Bunduc S et al (2023) Nabiximols is efficient as add-on treatment for patients with multiple sclerosis spasticity refractory to standard treatment: a systematic review and meta-analysis of randomised clinical trials. Curr Neuropharmacol. https://doi.org/10.2174/1570159X21666230727094431 – DOI – PubMed – PMC
    1. Nicholas J, Lublin F, Klineova S et al (2023) Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials. Mult Scler Relat Disord 75:104745. https://doi.org/10.1016/j.msard.2023.104745 – DOI – PubMed
    1. Rice J, Cameron M (2018) Cannabinoids for treatment of MS symptoms: state of the evidence. Curr Neurol Neurosci Rep 18:50. https://doi.org/10.1007/s11910-018-0859-x – DOI – PubMed

LinkOut – more resources

Leave a Reply